| scholarly article | Q13442814 |
| P50 | author | Ioannis A. Voutsadakis | Q61115003 |
| Gianluigi Mazzoccoli | Q42322811 | ||
| P2093 | author name string | Athina Stravodimou | |
| P2860 | cites work | Molecular regulation of pancreatic stellate cell function | Q21093285 |
| RNF34 is a cold-regulated E3 ubiquitin ligase for PGC-1α and modulates brown fat cell metabolism | Q24296350 | ||
| Control of adipogenesis by the SUMO-specific protease SENP2 | Q24301429 | ||
| Down-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferation | Q24304940 | ||
| HECT and RING finger families of E3 ubiquitin ligases at a glance | Q24599672 | ||
| Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways | Q24647626 | ||
| The epithelial-mesenchymal transition generates cells with properties of stem cells | Q24650786 | ||
| The basics of epithelial-mesenchymal transition | Q24652992 | ||
| Rapid turnover of extracellular signal-regulated kinase 3 by the ubiquitin-proteasome pathway defines a novel paradigm of mitogen-activated protein kinase regulation during cellular differentiation | Q24683060 | ||
| Non-canonical ubiquitin-based signals for proteasomal degradation | Q26825366 | ||
| SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer | Q27851475 | ||
| Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma. | Q51756137 | ||
| Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. | Q52929346 | ||
| Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract | Q73685169 | ||
| Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes | Q74371216 | ||
| Mutant p53 gain of function is interwoven into the hallmarks of cancer | Q82183156 | ||
| Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2. | Q40260486 | ||
| Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation | Q40293114 | ||
| Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system | Q40302475 | ||
| Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells | Q40436319 | ||
| Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. | Q40449143 | ||
| The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells | Q40507359 | ||
| Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2. | Q40577066 | ||
| Differential ubiquitination defines the functional status of the tumor suppressor Smad4. | Q40641509 | ||
| Cell adhesion protects c-Raf-1 against ubiquitin-dependent degradation by the proteasome | Q40723737 | ||
| Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. | Q40744675 | ||
| PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner | Q42800039 | ||
| Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation | Q42803719 | ||
| Interdomain communication regulating ligand binding by PPAR-gamma | Q42823872 | ||
| Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. | Q43621579 | ||
| Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone | Q43820996 | ||
| Activation of PPARgamma increases PTEN expression in pancreatic cancer cells | Q44283207 | ||
| PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway | Q44493760 | ||
| Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway | Q44563860 | ||
| Proteasome‐dependent decrease in Akt by growth factors in vascular smooth muscle cells | Q44641479 | ||
| Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells. | Q44920013 | ||
| PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study | Q46639344 | ||
| Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2 | Q28209990 | ||
| The organization, promoter analysis, and expression of the human PPARgamma gene | Q28244071 | ||
| A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors | Q28246411 | ||
| TGFbeta in Cancer | Q28288866 | ||
| Retracted: Activated K-ras and INK4a/Arf Deficiency Cooperate During the Development of Pancreatic Cancer by Activation of Notch and NF-κB Signaling Pathways | Q28478427 | ||
| Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF(Fbx4/alphaB-crystallin) ligase and subsequent proteasome-dependent degradation | Q28508267 | ||
| The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2 | Q28576814 | ||
| A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma | Q28593737 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Pancreatic cancer | Q29616288 | ||
| PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines | Q29620217 | ||
| The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation | Q29620219 | ||
| Inflammation meets cancer, with NF-κB as the matchmaker | Q29620242 | ||
| Ras history: The saga continues | Q30404024 | ||
| Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition | Q30498249 | ||
| Substrate specificity of the human proteasome | Q30783959 | ||
| Small-molecule inhibitors of MDM2 as new anticancer therapeutics | Q33515500 | ||
| PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis | Q33799182 | ||
| Proteasomal degradation of retinoid X receptor alpha reprograms transcriptional activity of PPARgamma in obese mice and humans | Q33815655 | ||
| Peroxisome proliferator-activated receptors alpha, Beta, and gamma mRNA and protein expression in human fetal tissues | Q34035410 | ||
| Constructing and decoding unconventional ubiquitin chains. | Q34182233 | ||
| Generation and physiological roles of linear ubiquitin chains | Q34197025 | ||
| Signaling-mediated control of ubiquitin ligases in endocytosis. | Q34197088 | ||
| Thiazolidinediones | Q34346862 | ||
| Hepatotoxicity with thiazolidinediones: is it a class effect? | Q34458520 | ||
| The complexities of obesity and diabetes with the development and progression of pancreatic cancer | Q34669361 | ||
| Controversy: PPARgamma as a target for treatment of colorectal cancer | Q34744898 | ||
| The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins | Q35014611 | ||
| Differentiation potential of pancreatic fibroblastoid cells/stellate cells: effects of peroxisome proliferator-activated receptor gamma ligands | Q35294964 | ||
| Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice | Q35578568 | ||
| Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms | Q35596926 | ||
| Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? | Q35606829 | ||
| Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma | Q35641787 | ||
| Cullin 3 mediates SRC-3 ubiquitination and degradation to control the retinoic acid response | Q35651231 | ||
| Regulation of peroxisome proliferator-activated receptor-γ by angiotensin II via transforming growth factor-β1-activated p38 mitogen-activated protein kinase in aortic smooth muscle cells | Q35683079 | ||
| No one can whistle a symphony alone - how different ubiquitin linkages cooperate to orchestrate NF-κB activity | Q37990496 | ||
| Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer | Q37991651 | ||
| The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer | Q38029132 | ||
| Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase | Q38346718 | ||
| PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network | Q38626764 | ||
| Molecular predictors of gemcitabine response in pancreatic cancer | Q39250668 | ||
| Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells | Q39363307 | ||
| PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells | Q39454094 | ||
| Bid as a potential target of apoptotic effects exerted by low doses of PPARγ and RXR ligands in breast cancer cells. | Q39528455 | ||
| Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells | Q39631194 | ||
| Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility | Q39915251 | ||
| SOCS 3 and PPAR-gamma ligands inhibit the expression of IL-6 and TGF-beta1 by regulating JAK2/STAT3 signaling in pancreas | Q40045550 | ||
| SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock | Q40118969 | ||
| Involvement of PPAR-gamma and p53 in DHA-induced apoptosis in Reh cells. | Q40135452 | ||
| Partners in crime: the TGFβ and MAPK pathways in cancer progression. | Q35744886 | ||
| Emerging regulatory mechanisms in ubiquitin-dependent cell cycle control. | Q35770195 | ||
| Non-degradative ubiquitination in Smad-dependent TGF-β signaling | Q35800181 | ||
| Post-translational modifications of nuclear receptors and human disease | Q35842790 | ||
| Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity | Q35874237 | ||
| Transforming growth factor-β inhibits myocardial PPARγ expression in pressure overload-induced cardiac fibrosis and remodeling in mice | Q35885246 | ||
| Regulation of TGF-β receptor activity | Q35905598 | ||
| The proteasome: a proteolytic nanomachine of cell regulation and waste disposal | Q35967536 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| Phosphorylation of PPARs: from molecular characterization to physiological relevance | Q36055786 | ||
| The potential of antidiabetic thiazolidinediones for anticancer therapy | Q36568732 | ||
| Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis | Q36894553 | ||
| Synergy between PPARgamma ligands and platinum-based drugs in cancer | Q36930841 | ||
| Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition | Q37122334 | ||
| Polyubiquitin chains: functions, structures, and mechanisms | Q37148338 | ||
| The molecular biology of pancreatic cancer | Q37153303 | ||
| Regulation of TGF-beta family signaling by E3 ubiquitin ligases | Q37276098 | ||
| SUMOylation attenuates the function of PGC-1alpha | Q37377783 | ||
| Principles of ubiquitin and SUMO modifications in DNA repair. | Q37424808 | ||
| Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer | Q37449396 | ||
| Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer? | Q37629933 | ||
| Inflammation and EMT: an alliance towards organ fibrosis and cancer progression | Q37668231 | ||
| The diversity of ubiquitin recognition: hot spots and varied specificity | Q37764527 | ||
| The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance | Q37767875 | ||
| Development of target-specific treatments in multiple myeloma | Q37771370 | ||
| Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation | Q37791438 | ||
| Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer | Q37827165 | ||
| Non-genomic loss of PTEN function in cancer: not in my genes. | Q37828766 | ||
| Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer | Q37880852 | ||
| SUMO playing tag with ubiquitin | Q37948388 | ||
| Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression | Q37970379 | ||
| Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells | Q37982808 | ||
| Ubiquitin and SUMO in DNA repair at a glance | Q37987407 | ||
| The role of ubiquitylation in receptor endocytosis and endosomal sorting | Q37987408 | ||
| Cellular functions of the DUBs | Q37987409 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | pancreatic cancer | Q212961 |
| ubiquitin-proteasome system | Q47175589 | ||
| P304 | page(s) | 367450 | |
| P577 | publication date | 2012-09-19 | |
| P1433 | published in | PPAR Research | Q15756406 |
| P1476 | title | Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer | |
| P478 | volume | 2012 |
| Q36413867 | Crocetinic acid inhibits hedgehog signaling to inhibit pancreatic cancer stem cells. |
| Q35907145 | Inhibition of Prostaglandin Reductase 2, a Putative Oncogene Overexpressed in Human Pancreatic Adenocarcinoma, Induces Oxidative Stress-Mediated Cell Death Involving xCT and CTH Gene Expressions through 15-Keto-PGE2 |
Search more.